ANGLE plc (AGL) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: 29.64%
• EPS Growth: 28.51%
• Country: UK
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: N/A
• EPS (TTM): -0.03
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.06
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 10.56
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $2.50 ▲(35.14% Upside)

ANGLE plc's overall stock score is primarily impacted by its poor financial performance, with declining revenues and profitability issues being the most significant factors. Technical analysis also indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio. While the earnings call provided some positive developments, these are overshadowed by the financial and market challenges.

Positive Factors

Pharma Collaborations

These collaborations validate the Parsortix system's utility and enhance ANGLE's credibility, potentially leading to more partnerships and revenue opportunities.

MedTech Collaboration

This collaboration offers potential for large-scale commercialization, expanding market reach and driving long-term revenue growth.

Cost Management

Effective cost management extends cash runway, supporting ongoing operations and strategic initiatives without immediate financial strain.

Negative Factors

Revenue Decline

Declining revenue indicates market challenges and slower decision-making, potentially impacting future growth and financial stability.

Need for Additional Funding

The need for additional funding highlights potential liquidity issues, which could limit operational flexibility and investment in growth initiatives.

Negative Profitability Metrics

Ongoing operational inefficiencies and negative profitability metrics suggest challenges in achieving sustainable profitability, impacting long-term viability.

ANGLE plc Business Overview & Revenue Model

Company Description

How the Company Makes Money

ANGLE plc generates revenue through the sale of its Parsortix systems and related consumables, including the CTC harvesting kits. The company also earns income from service contracts, collaborations with academic institutions, and pharmaceutical companies engaged in research and clinical trials. Significant partnerships with industry leaders enhance ANGLE's market presence and contribute to its earnings, as they facilitate access to larger client bases and shared research initiatives. Furthermore, ANGLE may also benefit from licensing agreements for its technologies, which can provide additional revenue streams.

ANGLE plc Financial Statement Overview

Summary

ANGLE plc is in a growth phase with improving revenues but persistent profitability challenges. The balance sheet shows a solid equity position with manageable leverage. However, negative cash flows highlight operational inefficiencies and the need for financial support.

Income Statement

ANGLE plc has shown moderate revenue growth over the past years, with a significant increase from $762,000 in 2020 to $2,862,000 in 2024. Gross profit margins have improved, but the net profit margin remains negative due to substantial operating losses. EBIT and EBITDA margins are also negative, indicating challenges in achieving operational profitability. The company is still in a growth phase, focusing on revenue increase while managing high operational costs.

Balance Sheet

The balance sheet of ANGLE plc indicates a stable equity base with a debt-to-equity ratio below industry averages, suggesting conservative leverage usage. The equity ratio remains strong, but declining cash reserves and increasing liabilities pose potential liquidity concerns. Overall, while the company has a solid equity foundation, monitoring cash and liabilities is crucial.

Cash Flow

Operating cash flows remain negative, reflecting ongoing operational challenges. Although there is a slight improvement in free cash flow over the years, it remains negative, indicating the need for external financing to support operations. The cash flow to net income ratios are not favorable, underscoring difficulties in generating sufficient cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.62M	2.86M	2.19M	1.04M	1.01M	762.00K
Gross Profit	1.63M	1.78M	-408.00K	613.00K	711.00K	597.00K
EBITDA	-15.60M	-13.02M	-19.48M	-22.06M	-15.74M	-12.29M
Net Income	-15.78M	-14.22M	-20.13M	-21.69M	-15.01M	-11.61M
Balance Sheet
Total Assets	18.08M	25.46M	31.18M	49.87M	47.31M	39.05M
Cash, Cash Equivalents and Short-Term Investments	5.27M	10.43M	16.22M	31.90M	31.84M	28.62M
Total Debt	3.67M	4.21M	4.55M	5.00M	2.34M	1.36M
Total Liabilities	6.39M	7.02M	8.24M	9.80M	6.99M	4.71M
Stockholders Equity	11.69M	18.44M	22.94M	40.06M	40.33M	34.34M
Cash Flow
Free Cash Flow	-11.62M	-13.89M	-15.12M	-17.94M	-15.80M	-8.35M
Operating Cash Flow	-11.25M	-13.45M	-14.46M	-16.05M	-14.01M	-7.85M
Investing Cash Flow	-491.50K	-48.00K	-203.00K	-1.75M	14.77M	-1.97M
Financing Cash Flow	-2.05M	7.67M	-1.13M	18.10M	18.99M	18.14M

ANGLE plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGL, the sentiment is Negative. The current price of 1.85 is below the 20-day moving average (MA) of 2.17, below the 50-day MA of 3.41, and below the 200-day MA of 7.51, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 43.71 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AGL.

ANGLE plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	£17.58M	―	-90.48%	―	37.39%	-126.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	51 Neutral	£10.04M	―	―	―	125.37%	22.47%
VRCI	46 Neutral	£9.46M	-0.26	-122.54%	―	-57.03%	-15.71%
PRM	40 Underperform	£5.92M	-1.56	―	―	12.19%	18.12%
AGL	40 Underperform	―	―	-87.18%	―	29.64%	28.51%
GENI	39 Underperform	£8.18M	-1.23	-181.41%	―	12.12%	54.24%

ANGLE plc Corporate Events

ANGLE plc Strengthens Leadership with Key Appointments

ANGLE plc has announced key appointments to strengthen its management team, naming Peter Collins as interim CEO and Klaas de Boer as a senior board advisor. Collins brings over 25 years of experience in oncology diagnostics, while de Boer’s expertise in finance and technology will support the company’s restructuring and funding efforts. These strategic hires are expected to enhance ANGLE’s operational capabilities and market positioning as it undergoes significant organizational changes.

The most recent analyst rating on (GB:AGL) stock is a Sell with a £2.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Announces Strategic Shift and Name Change to CelLBxHealth

ANGLE plc has announced a strategic shift, including a name change to CelLBxHealth plc, under the leadership of Dr. Jan Groen as Executive Chairman. The revised strategy aims to enhance the company’s focus on CTC intelligence, improve commercial traction, and maintain cost control, with a potential need to raise funds by Q1 2026. The company plans to capitalize on its Parsortix platform by developing applications that integrate with existing proteomics and genomic assays, targeting the pharmaceutical services and clinical diagnostics markets.

The most recent analyst rating on (GB:AGL) stock is a Sell with a £2.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc’s Parsortix System Shows Promise in Glioblastoma CTC Detection

ANGLE plc announced promising results from a proof-of-concept study using its Parsortix system to detect circulating tumor cells (CTCs) in glioblastoma patients. The study, presented at the 7th ACTC meeting, demonstrated that CTCs were detected in 60% of patients, with CTC clusters observed in 78% of CTC-positive cases, highlighting the system’s potential for minimally invasive monitoring. This advancement could significantly impact the treatment and monitoring of glioblastoma, offering new opportunities for targeted therapies and aiding pharmaceutical companies in drug development.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £4.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc’s Parsortix System Shows Promise in Glioblastoma CTC Detection

ANGLE plc announced promising results from a proof-of-concept study presented at the ACTC meeting, demonstrating the effectiveness of their Parsortix system in detecting circulating tumour cells (CTCs) in glioblastoma patients. This breakthrough could enable minimally invasive, real-time monitoring of tumour biology and disease progression, potentially transforming treatment approaches and supporting drug development in this high-need area.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £4.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Announces Leadership Reshuffle Amid Strategic Discussions

ANGLE plc announced significant board changes following discussions with a major shareholder, leading to the resignation of Chief Executive Andrew Newland and Finance Director Ian Griffiths. The company remains committed to ensuring a smooth transition, with Dr. Jan Groen and Dr. Joseph Eid continuing as non-executive members of the board. These changes may impact ANGLE’s strategic direction and stakeholder confidence, as the company plans to expand its board in the future.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £4.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Earnings Call: Progress Amid Challenges

ANGLE plc’s recent earnings call painted a picture of both progress and challenges. The company highlighted significant achievements in pharmaceutical collaborations and technology advancements, yet acknowledged the hurdles posed by adverse market conditions impacting revenue and the necessity for additional funding.

ANGLE plc Reports Interim Results Amid Market Challenges and Strategic Advances

ANGLE plc reported interim results for the first half of 2025, highlighting successful completion of contracts with major pharma companies like Eisai and AstraZeneca, despite facing revenue pressures due to adverse market conditions. The company has developed a unique DNA dual analysis assay using Illumina NGS, expanding its market reach and enhancing its product offerings. ANGLE continues to face challenges from external conditions such as US policy volatility and tariff uncertainties, which have delayed new projects and collaborations. However, the company remains optimistic about its growth potential with ongoing discussions for new contracts and collaborations, including a significant partnership with Myriad Genetics to adapt a cancer test to a CTC-based sample using ANGLE’s Parsortix system.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Appoints Cavendish as Nominated Adviser and Sole Broker

ANGLE plc has appointed Cavendish Capital Markets Limited as its Nominated Adviser and Sole Broker, effective immediately. This strategic move is expected to enhance ANGLE’s market positioning and potentially impact its operations positively by leveraging Cavendish’s expertise in corporate finance and life sciences, benefiting stakeholders and supporting the company’s growth in the liquid biopsy industry.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc to Announce Interim Results Amid Virtual Meeting

ANGLE plc announced it will release its interim results for the first half of 2025 on September 9, 2025. Due to planned tube strikes, the analyst meeting will be held virtually, with a live webcast available for analysts. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning in the liquid biopsy industry.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

ANGLE plc Collaborates with Myriad Genetics to Enhance Cancer Diagnostics

ANGLE plc has announced a collaboration with Myriad Genetics to assess the feasibility of using Parsortix-derived circulating tumour cell (CTC) DNA alongside Myriad’s existing tissue-based diagnostic test. This partnership aims to enhance patient treatment by improving access to genomic data through a simple blood test, potentially impacting the precision medicine field significantly.

The most recent analyst rating on (GB:AGL) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.